New tyk2 inhibitors have shown high clearance rates in treating psoriasis in randomized trials. Some outlets report on specific oral tyk2 inhibitors, such as envudeucitinib and esk-001, achieving positive results. The effectiveness of these inhibitors has sparked interest, with some considering them a potential alternative to existing treatments, although it is unclear how they will be used in practice.